State Board of Administration of Florida Retirement System Acquires 150 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

State Board of Administration of Florida Retirement System lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 0.1% in the third quarter, HoldingsChannel reports. The firm owned 107,197 shares of the company’s stock after purchasing an additional 150 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Neurocrine Biosciences were worth $12,060,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth about $27,000. KB Financial Partners LLC purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at about $32,000. BluePath Capital Management LLC purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth $35,000. Covestor Ltd boosted its position in Neurocrine Biosciences by 431.0% during the first quarter. Covestor Ltd now owns 377 shares of the company’s stock valued at $35,000 after purchasing an additional 306 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in Neurocrine Biosciences by 755.0% in the fourth quarter. Bessemer Group Inc. now owns 342 shares of the company’s stock worth $42,000 after purchasing an additional 302 shares in the last quarter. Hedge funds and other institutional investors own 93.54% of the company’s stock.

Neurocrine Biosciences Stock Performance

NBIX opened at $130.43 on Tuesday. The stock has a market capitalization of $12.81 billion, a price-to-earnings ratio of 53.90, a PEG ratio of 0.84 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $143.35. The company has a fifty day moving average of $131.58 and a 200 day moving average of $117.72.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 earnings per share. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.89 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on NBIX shares. Barclays lifted their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Neurocrine Biosciences in a report on Tuesday, October 24th. Piper Sandler lifted their price objective on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Wells Fargo & Company upped their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a report on Thursday, February 8th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, December 12th. They issued a “buy” rating and a $136.00 price objective for the company. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $136.69.

Check Out Our Latest Stock Report on Neurocrine Biosciences

Insider Activity at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 10,919 shares of the firm’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $112.27, for a total transaction of $1,225,876.13. Following the sale, the insider now owns 35,882 shares of the company’s stock, valued at approximately $4,028,472.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Neurocrine Biosciences news, CFO Matt Abernethy sold 1,280 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $142.19, for a total transaction of $182,003.20. Following the sale, the chief financial officer now owns 29,434 shares of the company’s stock, valued at $4,185,220.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Darin Lippoldt sold 10,919 shares of Neurocrine Biosciences stock in a transaction on Monday, November 27th. The shares were sold at an average price of $112.27, for a total transaction of $1,225,876.13. Following the completion of the transaction, the insider now owns 35,882 shares in the company, valued at $4,028,472.14. The disclosure for this sale can be found here. Insiders have sold a total of 279,989 shares of company stock worth $36,339,235 over the last quarter. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Further Reading

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.